Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2004

View Archived Issues

Histone deacetylase inhibitor effective against esophageal carcinoma in vitro

Genzyme to buy back certain Synvisc rights from Wyeth

Novel macrolides effective against multiresistant strains of pneumococci and H. influenzae

New approval for Eloxatin

Phenoxodiol receives fast track status for recurrent ovarian cancer

Ferrer to distribute Barrier's products

Treatment of multifactor anemia by hypoxia-inducible factor inhibitor

Phase II trials in Canada, E.U. evaluate AMD-3100 for stem cell transplantation

Dynogen acquires pumosetrag from Mitsubishi Pharma

Norditropin approved for adults with severe growth hormone deficiency

CytoGenix submits pre-IND brief for antiherpes drug CY-301

Add-on therapy with Reverset reduces viral load in HIV-infected patients

GX-015-070 enters phase I

Inspire licenses novel glaucoma technology

AstraZeneca to resubmit Symbicort Single Inhaler Therapy file in E.U.

Marqibo submitted for marketing approval in Canada

Phase II data support 873140 as an antiviral for HIV infection

Affimed Therapeutics and Syngenta to codevelop Tandab antibody

Results of PROTECT trial of Integrilin

New data on the benefits of Ampligen in chronic fatigue syndrome

Rifalazil shows promise in the treatment of Chlamydia infections

New data on the pharmacokinetics and tolerability of the neuromuscular blocker AV-430A

Long-term benefits of ranibizumab in neovascular AMD patients

Improved visual acuity found with ruboxistaurin in DME involving the center of macula

New PPARgamma activators and their use in type 2 diabetes and metabolic syndrome

Indian researchers isolate new cytotoxic terpenes from plants

New chiral antiarrhythmic agent covered by Aventis patent

ARS scientists prepare and test novel amylin antiaggregatory peptides

New cathepsin S inhibitors in early development at Boehringer Ingelheim

New elastase release inhibitors described by Taisho and U. of Texas scientists

Adolor claims novel opioid antagonists for use in GI disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...